Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis

BMC Neuroscience

Volumn 13, Issue 1, 2012, Pages

  Müller, André M ^a   Jun, Esther ^a   Conlon, Hana ^a   Sadiq, Saud A ^a  

^a Multiple Sclerosis Research Center of New York Inc   (United States)

Author keywords

EAE; Multiple sclerosis; SLPI; TGF beta

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; CYTOKINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; OVALBUMIN; RECOMBINANT PROTEIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; SLPI PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL STRAIN U937; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; INFLAMMATION; LYMPH NODE; LYMPHOCYTE CULTURE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; RAT; REGULATORY T LYMPHOCYTE; SERUM; VACCINATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INFLAMMATION; MICE; RATS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 84860914791     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-13-30     Document Type: Article

References (31)

1. Fritz H. Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). BiolChem Hoppe Seyler 1988, 369(Suppl):79-82.
2. Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, Barone FC, Feuerstein GZ. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. MolPharmacol 2003, 64:833-840.
3. Mueller AM, Pedre X, Stempfl T, Kleiter I, Couillard-Despres S, Aigner L, Giegerich G, Steinbrecher A. Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis. J Neuroinflammation 2008, 5:20. 10.1186/1742-2094-5-20, 2438345, 18501024.
4. Layland LE, Mages J, Loddenkemper C, Hoerauf A, Wagner H, Lang R, da Costa CU. Pronounced phenotype in activated regulatory T cells during a chronic helminth infection. Journal of immunology 2010, 184:713-724.
5. Urso ML, Chen YW, Scrimgeour AG, Lee PC, Lee KF, Clarkson PM. Alterations in mRNA expression and protein products following spinal cord injury in humans. J Physiol 2007, 579:877-892. 10.1113/jphysiol.2006.118042, 2151363, 17218363.
6. Zitnik RJ, Zhang J, Kashem MA, Kohno T, Lyons DE, Wright CD, Rosen E, Goldberg I, Hayday AC. The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. BiochemBiophys Res Commun 1997, 232:687-697.
7. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996, 64:4520-4524. 174407, 8890201.
8. Shine N, Konopka K, Duzgunes N. The anti-HIV-1 activity associated with saliva. J Dent Res 1997, 76:634-640. 10.1177/00220345970760020301, 9062556.
9. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill SJ, McElvaney NG. Secretory leucoprotease inhibitor binds to NF-{kappa}B binding sites in monocytes and inhibits p65 binding. The Journal of experimental medicine 2005, 202:1659-1668. 10.1084/jem.20050768, 2212970, 16352738.
10. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM, Santini PA, Cerutti A. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nature immunology 2007, 8:294-303. 10.1038/ni1434, 17259987.
11. Ward PA, Lentsch AB. Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 2002, 234-235:225-228. 10.1023/A:1015944709177, 12162438.
12. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997, 99:894-900. 10.1172/JCI119254, 507897, 9062347.
13. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000, 6:1147-1153. 10.1038/80489, 11017147.
14. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J BiolChem 2002, 277:29999-30009.
15. Tateosian NL, Reiteri RM, Amiano NO, Costa MJ, Villalonga X, Guerrieri D, Maffia PC. Neutrophil elastase treated dendritic cells promote the generation of CD4(+)FOXP3(+) regulatory T cells in vitro. Cell Immunol 2011, 269:128-134. 10.1016/j.cellimm.2011.03.013, 21477798.
16. Prat A, Antel J. Pathogenesis of multiple sclerosis. CurrOpinNeurol 2005, 18:225-230.
17. Sadiq SA. Multiple Sclerosis. Merritt's Neurology 941-963. Philadelphia: Lippincott Williams and Wilkins, Rowland LP, 11, 3316589, 22479512.
18. Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 159:55-65. 10.1016/j.jneuroim.2004.10.001, 15652403.
19. Wright CD, Kennedy JA, Zitnik RJ, Kashem MA. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. BiochemBiophys Res Commun 1999, 254:614-617.
20. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochimica et biophysica acta 2011, 1812:275-282.
21. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006, 6:541-550. 10.1038/nri1841, 16799473.
22. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629. 10.1038/nri1418, 15286728.
23. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006, 203:1007-1019. 10.1084/jem.20051342, 2118280, 16585265.
24. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. NeurosciLett 1995, 201:223-226.
25. Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. J NeurolSci 2008, 271:191-202.
26. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ. Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 1999, 117:953-961. 10.1016/S0016-5085(99)70355-0, 10500079.
27. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992, 38:229-240. 10.1016/0165-5728(92)90016-E, 1376328.
28. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998, 8:681-694.
29. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nature reviews Immunology 2010, 10:554-567. 10.1038/nri2808, 20616810.
30. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991, 146:3012-3017.
31. Komura E, Tonetti C, Penard-Lacronique V, Chagraoui H, Lacout C, Lecouedic JP, Rameau P, Debili N, Vainchenker W, Giraudier S. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005, 65:3281-3289.